Eriodictyol Suppresses Gastric Cancer Cells via Inhibition of PI3K/AKT Pathway

Round 1

Reviewer 1 Report

The manuscript entitled “Eriodictyol suppresses gastric cancer cells via inhibition of PI3K/AKT pathway”  investigated the anti-cancer effects of eriodictyol towards GC both in vitro and in vivo.

The manuscript is very interesting and well-written. However, minor revisions should be made in order to be published in Pharmaceuticals journal, and the manuscript should be completed and/or modified taking into account the suggestions below:

1.      The authors are advised to rephrase the sentences from lines 37-39, 58-60, 145-146  

2.      The authors are advised to change the following sentence: „Nevertheless, the anti-cancer activity and potential targets of eriodictyol have not been well studied” (lines 62-63), since several papers investigated theese effects (references 29, 31, 33)

3.      The authors are advised to better explain  how they choose the doses of eriodictyol (100-200mg/kg) for 4.7. Xenograft Tumor Model

4.      The authors are advised to add details about the standards used (eriodictyol, quercetin, taxifolin and kaempferol)

Author Response

Please see the attachment。

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript "Eriodictyol suppresses gastric cancer cells via inhibition of  PI3K/AKT pathway" reports new findings worthy of publication in Processes. Before publishing the data in Processes, the reviewer thinks several points should be corrected.

Concerns & Suggestions:

1. If a non-tumoral cell line is evaluated to determine the selectivity, authors should also test compounds in five concentrations, to determine the IC₅₀ values at 24 h, 48 h and 72 h.

2.  In the manuscript the authors didn’t mention how to get Eriodictyol and how about the purity? This raises a question mark about it’s purity and hence relevance and reliability of the biological results.

Author Response

Please see the attachment.

Author Response File: Author Response.docx